SEARCH

SEARCH BY CITATION

References

  • 1
    Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs1994;48:583598.
  • 2
    Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol1997;80:11B20B.
  • 3
    Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther1994;56:377388.
  • 4
    Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2–4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J2002;23:550557.
  • 5
    De Luca G, van ‘t Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J2004;25:10091013.
  • 6
    De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. Circulation2004;109:12231225.
  • 7
    De Luca G, Ernst N, Suryapranata H, et al. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty. Am J Cardiol2005;95:13611363.
  • 8
    Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: A study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol2005;46:12291235.
  • 9
    Stone GW, Dixon SR, Grines CL, et al. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol2007;100:13701375.
  • 10
    Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med2007;357:16311638.
  • 11
    Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future?JAMA2005;293:979986.
  • 12
    De Luca G, Ernst N, vant 't Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J2006;151:12561259.
  • 13
    Dangas G, Aymong ED, Mehran R, et al.; CADILLAC Investigators. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol2004;94:983988.
  • 14
    De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol2008;126:3744.
  • 15
    Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation2006;113:28032809.
  • 16
    Suryapranata H, De Luca G, van ‘t Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart2005;91:641645.
  • 17
    Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation2004;109:17041706.
  • 18
    van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F; On the behalf of the Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Myocardial Blush Grade. Circulation1998;97:23022306.
  • 19
    Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol2002;39:591597.
  • 20
    De Luca G, van 't Hof AW, Ottervanger JP, et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J2005;150:557562.
  • 21
    Sakuma T, Leong-Poi H, Fisher NG, et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: The role of microthromboemboli. J Am Soc Echocardiogr2003;16:1521.
  • 22
    Limbruno U, De Carlo M, Pistolesi S, et al. Distal embolization during primary angioplasty: Histopathologic features and predictability. Am Heart J2005;150:102108.
  • 23
    Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: Predictors of slow-flow and no-reflow phenomenon. Chest2002;122:13221332.
  • 24
    Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol2003;92:728732.
  • 25
    Stone GW, Webb J, Cox DA, et al.; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: A randomized controlled trial. JAMA2005;293:10631072.
  • 26
    Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J2002;23:11121117.
  • 27
    Napodano M, Ramondo A, Tarantini G, et al. Predictors and time-related impact of distal embolization during primary angioplasty. Eur Heart J2009;30:305313.
  • 28
    De Luca G, Suryapranata H, de Boer MJ, et al. Impact of vessel size on distal embolization, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. J Thromb Thrombolysis2009;27:198203.
  • 29
    Dreyer W, Michael L, West M. Neutrophil accumulation in ischemic canine myocardium: Insights into the time course, distribution, and mechanism of localization during early reperfusion. Circulation1991;84:400411.
  • 30
    Kloner RA, Giacomelli F, Alker KJ, Hale SL, Matthews R, Bellows S. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation1991;84:17581772.
  • 31
    Brown KK, Henson PM, Maclouf J, Moyle M, Ely JA, Worthen GS. Neutrophil-platelet adhesion: Relative roles of platelet P-selectin and neutrophil b2 (CD18) integrins. Am J Respir Cell Mol Biol1998;18:100110.
  • 32
    Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the b2-integrin CD11b/CD18. Blood1996;88:146157.
  • 33
    Sheikh S, Nash GB. Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Blood1996;87:50405050.
  • 34
    Ward BJ, McCarthy A. Endothelial cell “swelling” is ischaemia and reperfusion. J Mol Cell Cardiol1995;27:12931300.
  • 35
    Ma XL, Weyrich AS, Lefer DJ, Beurke M, Albertine KH, Kishimoto TK, Lefer AM. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation1993;88:649658.
  • 36
    Tomai F, Ribichini F, Ghini AS, et al. Elevated C-Reactive Protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur Heart J2005;26:20992105.
  • 37
    Schindler TH, Nitzsche EU, Olschewski M. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation2004;110:10691075.
  • 38
    Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol1983;111:98111.
  • 39
    Engler RL. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion. Am J Cardiol1989;63(Suppl):19E23E.
  • 40
    Schorer A, Weber A. Comparative pharmacology of Gp IIb-IIIa inhibitors. J Thromb and Thrombolysis2003;15:7180.
  • 41
    Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J1999;138:S1S5.
  • 42
    Schwarz M, Nordt T, Bode C, et al. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res2002;107:121128.
  • 43
    Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol2005;46:986993.
  • 44
    Marcucci R, Paniccia R, Antonucci E, et al. usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol2006;98:11561159.
  • 45
    Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ2008;336:195198.
  • 46
    Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J2006;27:647654.
  • 47
    Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol2007;49:23122317.
  • 48
    Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J2007;154:221231.
  • 49
    Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol2006;48:13391345.
  • 50
    Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?Catheter Cardiovasc Interv2003;59:2125.
  • 51
    Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost2007;5:7581.
  • 52
    Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation2003;107:29082913.
  • 53
    Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol2007;50:18221834.
  • 54
    Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood1991;78:154162.
  • 55
    Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation2000;102:10071013.
  • 56
    Blanche D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol1995;268:H679H685.
  • 57
    Ichiki K, Ikeda H, Haramaki N, et al. Long-term smoking impairs platelet-derived nitric oxide release. Circulation1996;94:31093114.
  • 58
    Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol1998;31:352358.
  • 59
    Weber AA, Zimmermann KC, Kirchrath JM, et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet1999;353:900.
  • 60
    Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost2005;10:23402345.
  • 61
    Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation2000;101:10131018.
  • 62
    Patrono C, FitzGerald GA. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol1997;17:23092315.
  • 63
    Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation2003;108:989995.
  • 64
    Taubert D, Kastrati A, Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost2004;92:311316.
  • 65
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol2006;26;18951900.
  • 66
    Beitelshees AL, McLeod ML. Clopidogrel pharmacogenetics: Promising steps towards patient care?Arterioscler Thromb Vasc Biol 2006;26:16811683.
  • 67
    Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15:427433.
  • 68
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol2007;49:15051516.
  • 69
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2007;357:20012015.
  • 70
    Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet2008;371:13531363.
  • 71
    Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2009;361:10451057.
  • 72
    Cannon CP, Harrington RA, James S, et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet2010;375:283293.
  • 73
    Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation1998;98:26952701.
  • 74
    Petronio AS, Rovai D, Musumeci G, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J2003;24:6776.
  • 75
    Brener SJ, Ban LA, Burchenal JEB, et al.; On the behalf of the RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation1998;98:734741.
  • 76
    Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol2000;35:915921.
  • 77
    Montalescot G, Barragan P, Wittemberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med2001;344:18951903.
  • 78
    Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J2002;143:334341.
  • 79
    Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol2002;90:533536.
  • 80
    Lee CW, Moon DH, Hong MK, et al. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol2002;90:12431246.
  • 81
    Stone G, Grines CL, Cox AD, et al.; For the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med2002;346:957966.
  • 82
    Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J2005;150:1015.
  • 83
    De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA2005;293:17591765.
  • 84
    Mehilli J, Kastrati A, Schulz S, et al.; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation2009;119:19331940.
  • 85
    De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trials. J Am Coll Cardiol2006;7:685686.
  • 86
    De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomized trials. Eur Heart J2009;30:27052713.
  • 87
    De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost2005;93:820823.
  • 88
    Steen H, Lehrke S, Wiegand UK, et al. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J2005;149:564-e1564-e7.
  • 89
    Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol2004;44:11871193.
  • 90
    Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol2004;94:3539.
  • 91
    Valgimigli M, Percoco G, Malagutti P, et al.; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA2005;293:21092117.
  • 92
    Valgimigli M, Bolognese L, Anselmi M, et al. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: Design and rationale for the MULTI-STRATEGY trial. Am Heart J2007;154:3945.
  • 93
    Marzocchi A, Manari A, Piovaccari G, et al.; FATA Investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: Results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J2008;29:29722980.
  • 94
    Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: Results of the EVA-AMI Trial. J Am Coll Cardiol2010;56:463469.
  • 95
    De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-analysis. J Am Coll Cardiol2009;53:16681673.
  • 96
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: A meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv2009;2:230236.
  • 97
    Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv2004;62:186192.
  • 98
    Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation2008;118:4957.
  • 99
    Gu YL, Fokkema ML, Kampinga MA, de Smet BJ, Tan ES, van den Heuvel AF, Zijlstra F. Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: Rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trials2009;10:90.
  • 100
    Thiele H, Wöhrle J, Neuhaus P, et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators. Am Heart J2010;159:547554.
  • 101
    Stone GW, Witzenbichler B, Guagliumi G, et al.; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med2008;358:22182230.
  • 102
    Parodi G, De Luca G, Moschi G, et al. Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombol2010;30:446451.
  • 103
    De Luca G, Parodi G, Antoniucci D. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis. J Thromb Thrombol2010;30:452458.
  • 104
    Bolognese L. Effects of pre-treatment with abciximab on coronary artery patency and microcirculation in high risk patients with acute myocardial infarction eligible for primary angioplasty: Results of the Abciximab patients evaluation (APE) randomized pilot study. Circulation2000;10(Suppl A):150.
  • 105
    van't Hof AW, Ernst N, de Boer MJ, et al.; On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: Results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J2004;25:837846.
  • 106
    Gibson CM, Kirtane AJ, Murphy SA, et al.; TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J2006;152:668675.
  • 107
    Zeymer U, Zahn R, Schiele R, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J2005;26:19711977.
  • 108
    Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol2003;92:977980.
  • 109
    Lee DP, Herity NA, Hiatt BL, et al.; TIrofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation2003;107:14971501.
  • 110
    Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol2007;49:15171524.
  • 111
    Arntz HR, Schroder J, Schwimmbeck P, et al. Is early prehospital administration of abciximab superior to periprocedural therapy in patients with STEMI and planned PCI? Early and late results from the randomized REOMOBILE Pilot study. JACC2004;43(Suppl A):10021079.
  • 112
    Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv2006;68:218224.
  • 113
    Gyongyosi M, Domanovits H, Benzer W, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion—results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J2004;25:21252133.
  • 114
    Rakowski T, Zalewski J, Legutko J, et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study. Am Heart J2007;153:360365.
  • 115
    Emre A, Ucer E, Yesilcimen K, et al. Impact of early tirofiban on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology2006;106:264269.
  • 116
    Ellis SG, Tendera M, de Belder MA, et al.; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med2008;358:22052217.
  • 117
    Dudek D, Siudak Z, Janzon M, et al.; EUROTRANSFER Registry Investigators. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry. Am Heart J2008;156:11471154.
  • 118
    Ortolani P, Marzocchi A, Marrozzini C, et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: Results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J2009;30:3343.
  • 119
    Hassan AK, Liem SS, van der Kley F, et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: Results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv2009;74:335343.
  • 120
    Huber K, Aylward PE, van’t Hof AWJ, et al. Glycoprotein IIb-IIIa inhibitors before primary percutaneous coronary intervention of ST-elevation myocardial infarction improve perfusion and outcomes: Insights from APEX-AMI. Circulation2007;116:II-673 (Abstract).
  • 121
    De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart2008;94:15481558.
  • 122
    Van't Hof AW, Ten Berg J, Heestermans T, et al.; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet2008;372:537546.
  • 123
    Wijns W, Kolh P, Danchin N, et al.; European Association for Percutaneous Cardiovascular Interventions, Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2010;31:25012555.
  • 124
    Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol1992;19:10651069.
  • 125
    O’Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation1992;86:17101717.
  • 126
    Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J2000;21:823831.
  • 127
    Vermeer F, Ophuis A, Berg E, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: A safety and feasibility study. Heart1999;82:426431.
  • 128
    Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol1999;34:19541962.
  • 129
    Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Primary versus facilitated percutaneous coronary intervention (tenecteplase plus stenting) in patients with ST-elevated myocardial infarction: The final results of the GRACIA-2 randomized trial. Eur Heart J2007;25(Suppl):33 (Abstract).
  • 130
    ASSENT-4 PCI investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet2006;367;569578.
  • 131
    Kastrati A, Mehilli J, Schlotterbeck K, et al.; Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: A randomized controlled trial. JAMA2004;291:947954.
  • 132
    Wong A, Mak KH, Chan C, et al. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. Catheter Cardiovasc Interv2004;62:445452.
  • 133
    ADVANCE MI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J2005;150:116122.
  • 134
    Peters S, Truemmel M, Koehler B. Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: Results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial. Int J Cardiol2008;130:235240.
  • 135
    De Luca G, Marino P. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. Am J Emerg Med2009;27:683690.
  • 136
    Herrmann HC, Lu J, Brodie BR, et al.; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv2009;2:917924.
  • 137
    Ellis SG, Tendera M, de Belder MA, et al.; FINESSE Investigators. 1-Year survival in a randomized trial of facilitated reperfusion: Results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv2009;2:909916.
  • 138
    Di Mario C, Dudek D, Piscione F, et al.; CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): An open, prospective, randomised, multicentre trial. Lancet2008;371:559568.
  • 139
    Cantor WJ, Fitchett D, Borgundvaag B, et al.; TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med2009;360:27052718.
  • 140
    Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol2004;44:3843.
  • 141
    Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J2007;28:15981660.
  • 142
    Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: Results of the ISAR-REACT 2 randomized trial. Eur Heart J2008;29:455461.
  • 143
    Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST trial. J Am Coll Cardiol2006;47:522528.
  • 144
    Rasoul S, Ottervanger JP, de Boer MJ, et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: Results of the ELISA-2 trial. Eur Heart J2006;27:14011407.
  • 145
    Leoncini M, Toso A, Maioli M, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Am Heart J2005;150:401406.
  • 146
    Liu T, Xie Y, Zhou YJ, et al. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions. Chin Med J2009;122:17321737.
  • 147
    Stone GW, Ware JH, Bertrand ME, et al.; ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial. JAMA2007;298:24972506.
  • 148
    Giugliano RP, White JA, Bode C, et al.; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med2009;360:21762190.
  • 149
    De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol2011;107:198203.
  • 150
    Mehta SR, Granger CB, Boden WE, et al.; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med2009;360:21652175.
  • 151
    Bivalirudin/prasugrel versus abciximab/clopidogrel in patients presenting with STEMI. Available from: http://clinicaltrials.gov/ct2/show/NCT01158846?term=bivalirudin&rank=4 [Accessed 1 February 2011].
  • 152
    Randomized comparison of abciximab plus heparin with bivalirudin in acute coronary syndrome (ISAR-REACT-4). Available from: http://clinicaltrials.gov/ct2/show/NCT00373451?term=Kastrati&rank=2 [Accessed 1 February 2011].
  • 153
    Efficacy study of combined prasugrel and bivalirudin versus clopidogrel and heparin in myocardial infarction (BRAVE-4). Available from: http://clinicaltrials.gov/ct2/show/NCT00976092?term=BRAVE+4&rank=1 [Accessed 1 February 2011].